Chandrakant Lahariya

From Wikipedia, the free encyclopedia
Chandrakant Lahariya
Born1980s
Gwalior, India
NationalityIndian
EducationMedicine, Public Health, Public Policy
Alma materUniversity of Delhi , University of Geneva ,
Years active1998–present
Known forEpidemiology, Vaccinology and Immunology, Health systems
Notable work
Till We Win
TitleDoctor, Public Policy Expert, Author

Chandrakant Lahariya is an Indian medical doctor, epidemiologist, vaccinologist, public health, and policy expert and writer. His work centers around strengthening health systems, public policy interventions to address health inequities and to develop innovative models for health service delivery.[1][2][3]

Lahariya is the lead author of book Till We Win: India's Fight Against The COVID-19 Pandemic, with Randeep Guleria of AIIMS, New Delhi and Gagandeep Kang of Christian Medical College, Vellore.[4] He has been considered as one of the credible 'voices of reason' during COVID-19 pandemic in India.[5]

In early 2008, Lahariya joined the World Health Organization in India, where – for the next few years- he coordinated the organization's work on the new vaccines introduction in the country.[6][7] He specifically worked on the formulation of of India, and on the introduction of Haemophilus influenza type b (Hib)vaccine as well as scale up of Hepatitis B vaccine across the Indian states.[8][9][10]

Awards and recognitions[]

In the year 2012, he received Indian Council of Medical Research’s Dr B.C. Srivastava Foundation Award for his work on translating community-based health research into public policy interventions.[11]

In 2013, a former President of the Indian Academy of Pediatrics wrote about him that "I am impressed with Dr Chandrakant Lahariya for his work and vision to improve child survival in India. Dr Lahariya is a young, immensely talented and highly respected public health professional in India, who has significantly contributed to many activities of IAP including vaccinology courses, Mission Uday and has been a regular contributor to all major activities of IAP for last few years."[12]

In 2015, he became the youngest fellow ever elected to the Indian Public Health Association (IPHA).[13]

In October 2020, in a study conducted by Stanford University and published in the reputed PLoS Biology, Lahariya was listed amongst in top 2% of researchers globally, in the fields of Pediatrics and Public Health.[14]

Books and writing[]

Lahariya is the lead author of book Till We Win: India's Fight Against The COVID-19 Pandemic, with Randeep Guleria of AIIMS, New Delhi and Gagandeep Kang of Christian Medical College, Vellore.[4] The book has been published by the leading publisher Penguin Random House India and has become a bestseller. The book has been termed as "An easy to read and an important book driven by science, data and reason' by the editor in chief of India's leading newspaper the Hindustan Times.[5]

His opinion pieces are regularly published in the leading newspapers and online portals including The Indian Express, The Hindu and Dainik Bhaskar.[15][16]

In 2009-10, Lahariya was the Guest editor (along with Dr , the then Professor of Pediatrics at AIIMS, New Delhi and at present Member, , Govt. of India) of a special series on in India.[17][18][19] This series was published in the and had contribution from leading Indian health experts including , Deoki Nandan, Prasanna K Hota, & Shiv Lal. Lahariya had co-authored a few articles including one with Vinod K Paul.[20]

His seminal paper titled "A brief history of vaccines and vaccination in India", was published in the Indian Journal of Medical Research (IJMR) in April 2014. The journal is published by the Indian Council of Medical Research (ICMR). This paper is one of the highly cited as well as amongst the most comprehensive and authoritative published articles on vaccines and vaccination in India.[21]

Selected publications[]

  • Lahariya, Chandrakant; Sundararaman, T.; Ved, Rajani R.; Adithyan, G. S.; Graeve, Hilde De; Jhalani, Manoj; Bekedam, Henk (1 February 2020). "What makes primary healthcare facilities functional, and increases the utilization? Learnings from 12 case studies". Journal of Family Medicine and Primary Care. 9 (2): 539–546. doi:10.4103/jfmpc.jfmpc_1240_19. PMC 7114016. PMID 32318378.
  • Lahariya, Chandrakant; Roy, Bijit; Shukla, Abhay; Chatterjee, Mirai; Graeve, Hilde De; Jhalani, Manoj; Bekedam, Henk (1 January 2020). "Community action for health in India: evolution, lessons learnt and ways forward to achieve universal health coverage". WHO South-East Asia Journal of Public Health. 9 (1): 82–91. doi:10.4103/2224-3151.283002. PMID 32341227. S2CID 216594708.
  • Lahariya, Chandrakant (1 April 2014). "A brief history of vaccines & vaccination in India". Indian Journal of Medical Research. 139 (4): 491–511. PMC 4078488. PMID 24927336.
  • Lahariya, Chandrakant; Paul, Vinod K. (1 November 2010). "Burden, Differentials, and Causes of Child Deaths in India". The Indian Journal of Pediatrics. 77 (11): 1312–1321. doi:10.1007/s12098-010-0185-z. PMID 20830536. S2CID 3441068.
  • Mishra, Ashok; Mishra, Subodh; Jain, Pankaj; Bhadoriya, Rahul Singh; Mishra, Rakesh; Lahariya, Chandrakant (September 2008). "Measles related complications and the role of vitamin A supplementation". The Indian Journal of Pediatrics. 75 (9): 887–890. doi:10.1007/s12098-008-0089-3. PMID 18568439. S2CID 27703322.
  • Lahariya, Chandrakant (2007). "Global eradication of polio: the case for "finishing the job"". Bulletin of the World Health Organization. 85 (6): 487–492. doi:10.2471/BLT.06.037457. PMC 2636341. PMID 17639247.
  • Lahariya, Chandrakant; Pradhan, SK (March 2007). "Can Southeast Asia eradicate yaws by 2010? Some lessons from the Yaws Eradication Programme of India". The National Medical Journal of India. 20 (2): 81–6. CiteSeerX 10.1.1.603.3075. PMID 17802987.
  • Lahariya, C; Pradhan, SK (December 2006). "Emergence of chikungunya virus in Indian subcontinent after 32 years: A review". Journal of Vector Borne Diseases. 43 (4): 151–60. CiteSeerX 10.1.1.529.3451. PMID 17175699.
  • Lahariya, C; Sharma, AK; Pradhan, SK (April 2006). "Avian flu and possible human pandemic" (PDF). Indian Pediatrics. 43 (4): 317–25. CiteSeerX 10.1.1.455.4985. PMID 16651670.

References[]

  1. ^ "Lhmc.in". www77.lhmc.in.[unreliable source?]
  2. ^ ResearchGate
  3. ^ [1]
  4. ^ Jump up to: a b "Till We Win".
  5. ^ Jump up to: a b "Covid-19: What you need to know today". Hindustan Times. 11 December 2020.
  6. ^ "India's medical experts come together to pen a book titled 'Till We Win: India's Fight Against the Covid-19 Pandemic'". Mumbai Mirror. 24 November 2020.
  7. ^ Subcommittee on Introduction of Hib Vaccine in Universal Immunization Program, National Technical Advisory Group on Immunization, India (November 2009). "NTAGI subcommittee recommendations on Haemophilus influenzae type B (Hib) vaccine introduction in India" (PDF). Indian Pediatrics. 46 (11): 945–54. PMID 19955578.CS1 maint: multiple names: authors list (link)
  8. ^ Lahariya, Chandrakant; Subramanya, Bp; Sosler, Stephen (2013). "An assessment of hepatitis B vaccine introduction in India: Lessons for roll out and scale up of new vaccines in immunization programs". Indian Journal of Public Health. 57 (1): 8–14. doi:10.4103/0019-557X.111357. PMID 23649136.[non-primary source needed]
  9. ^ Gupta, Satish Kumar; Sosler, Stephen; Lahariya, Chandrakant (2012). "Introduction of Haemophilus Influenzae type b (Hib) as Pentavalent (DPT-HepB-Hib) Vaccine in Two States of India". Indian Pediatrics. 49 (9): 707–709. doi:10.1007/s13312-012-0151-0. PMID 23024078. S2CID 29677074.[non-primary source needed]
  10. ^ Lahariya, Chandrakant; Paruthi, Renu; Bhattacharya, Madhulekha (April 2016). "How a New Health Intervention Affects the Health Systems? Learnings from Pentavalent Vaccine Introduction in India". The Indian Journal of Pediatrics. 83 (4): 294–299. doi:10.1007/s12098-015-1844-x. PMID 26264631. S2CID 25707588.[non-primary source needed]
  11. ^ "Awardee Details". ICMR.
  12. ^ Bansal, C. P. (December 2013). "Tackling inequities in child survival in India: Let's meet at the horizon of pediatrics and public health". Indian Pediatrics. 50 (12): 1085–1086. doi:10.1007/s13312-013-0299-2. PMID 24413499. S2CID 28952975.
  13. ^ "Fellow Members – IPHA".
  14. ^ Ioannidis, John P. A.; Boyack, Kevin W.; Baas, Jeroen (16 October 2020). "Updated science-wide author databases of standardized citation indicators". PLOS Biology. 18 (10): e3000918. doi:10.1371/journal.pbio.3000918. PMC 7567353. PMID 33064726.
  15. ^ "Chandrakant Lahariya". September 23, 2020.[non-primary source needed]
  16. ^ Lahariya, Chandrakant (16 September 2020). "A paused vaccine trial is a good disruption". The Hindu.[non-primary source needed]
  17. ^ Dr. V. K. Paul, Professor
  18. ^ "Dr. V.K. Paul". AIIMS NEW.
  19. ^ "The Indian Journal of Pediatrics, Volume 77, Issue 3 - Springer". link.springer.com.[verification needed]
  20. ^ Lahariya, Chandrakant; Paul, Vinod K. (November 2010). "Burden, Differentials, and Causes of Child Deaths in India". The Indian Journal of Pediatrics. 77 (11): 1312–1321. doi:10.1007/s12098-010-0185-z. PMID 20830536. S2CID 3441068.[non-primary source needed]
  21. ^ Lahariya, Chandrakant (1 April 2014). "A brief history of vaccines & vaccination in India". Indian Journal of Medical Research. 139 (4): 491–511. PMC 4078488. PMID 24927336.[non-primary source needed]
Retrieved from ""